Buprenorphine adoption in the National Drug Abuse Treatment Clinical Trials Network.
The National Drug Abuse Treatment Clinical Trials Network (CTN), a collaborative federal research initiative that brings together universities and community-based treatment programs (CTPs), has conducted multiple clinical trials of buprenorphine for opioid dependence. Part of the CTN's mission is to promote the adoption of evidence-based treatment technologies. Drawing on a data collected during face-to-face interviews with administrators from a panel of 206 CTPs, this research examines the adoption of buprenorphine over a 2-year period. These data indicated that the adoption of buprenorphine doubled between the baseline and 24-month follow-up interviews. Involvement in a buprenorphine protocol continued to be a strong predictor of adoption at the 2-year follow-up, although adoption of buprenorphine tripled among those CTPs without buprenorphine-specific protocol experience. For-profit CTPs and those offering inpatient detoxification services were more likely to adopt buprenorphine over time. A small percentage of programs discontinued using buprenorphine. These findings point to the dynamic nature of service delivery in community-based addiction treatment and the continued need for longitudinal studies of organizational change.
Knudsen
Hannah K
HK
Department of Behavioral Science and Center on Drug and Alcohol Research, University of Kentucky, Lexington, KY 40536-0086, USA. hannah.knudsen@uky.edu
Abraham
Amanda J
AJ
Johnson
J Aaron
JA
Roman
Paul M
PM
D002047:Buprenorphine / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003299:Cooperative Behavior; D003625:Data Collection; D019317:Evidence-Based Medicine; D005500:Follow-Up Studies; D006801:Humans; D009292:Narcotic Antagonists / Q000627:therapeutic use*; D009293:Opioid-Related Disorders / Q000534:rehabilitation*; D016320:Substance Abuse Treatment Centers / Q000379:methods* / Q000639:trends; D014481:United States
D009292:Narcotic Antagonists; D002047:Buprenorphine